LIMBER

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
216 patients (estimated)
Sponsors
Incyte Corporation
Tags
Bromodomain and Extra-Terminal Protein (BET) Inhibitor, JAK1 Inhibitor, JAK2 Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1686
NCT Identifier
NCT04279847

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.